Contemporary survival of patients with pulmonary arterial hypertension and congenital systemic to pulmonary shunts

被引:22
|
作者
Vijarnsorn, Chodchanok [1 ]
Durongpisitkul, Kritvikrom [1 ]
Chungsomprasong, Paweena [1 ]
Bositthipichet, Densiri [1 ]
Ketsara, Salisa [1 ]
Titaram, Yuttapon [1 ]
Chanthong, Prakul [1 ]
Kanjanauthai, Supaluck [1 ]
Soongswang, Jarupim [1 ]
机构
[1] Mahidol Univ, Fac Med, Siriraj Hosp, Bangkok, Thailand
来源
PLOS ONE | 2018年 / 13卷 / 04期
关键词
HEART-DISEASE; EISENMENGER-SYNDROME; PREDICTORS; DIAGNOSIS; OUTCOMES; ADULTS; EPIDEMIOLOGY; MORTALITY; DEATH;
D O I
10.1371/journal.pone.0195092
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objective To compare survival of patients with newly diagnosed pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD) according to various clinical classifications with classifications of anatomical-pathophysiological systemic to pulmonary shunts in a single-center cohort. Methods All prevalent cases of PAH-CHD with hemodynamic confirmation by cardiac catheterization in 1995 +/- 2015 were retrospectively reviewed. Patients who were younger than three months of age, or with single ventricle following surgery were excluded. Baseline characteristics and clinical outcomes were retrieved from the database. The survival analysis was performed at the end of 2016. Prognostic factors were identified using multivariate analysis. Results A total of 366 consecutive patients (24.5 +/- 17.6 years of age, 40% male) with PAH-CHD were analyzed. Most had simple shunts (85 pre-tricuspid, 105 post-tricuspid, 102 combined shunts). Patients with pre-tricuspid shunts were significantly older at diagnosis in comparison to post-tricuspid, combined, and complex shunts. Clinical classifications identified patients as having Eisenmenger syndrome (ES, 26.8%), prevalent left to right shunt (66.7%), PAH with small defect (3%), or PAH following defect correction (3.5%). At followup (median = 5.9 years; 0.1-20.7 years), no statistically significant differences in survival rate were seen among the anatomical-pathophysiological shunts (p = 0.1). Conversely, the clinical classifications revealed that patients with PAH-small defect had inferior survival compared to patients with ES, PAH post-corrective surgery, or PAH with prevalent left to right shunt (p = 0.01). Significant mortality risks were functional class III, age < 10 years, PAH-small defect, elevated right atrial pressure > 15 mmHg, and baseline PVR > 8 WU.m.(2) Conclusion Patients with PAH-CHD had a modest long-term survival. Different anatomical-pathophysiological shunts affect the natural presentation, while clinical classifications indicate treatment strategies and survival. Contemporary therapy improves survival in deliberately selected patients.
引用
收藏
页数:18
相关论文
共 50 条
  • [21] Pulmonary arterial hypertension in systemic sclerosis
    Lechartier, Benoit
    Humbert, Marc
    PRESSE MEDICALE, 2021, 50 (01):
  • [22] Serum Chloride Levels Track With Survival in Patients With Pulmonary Arterial Hypertension
    Naal, Tawfeq
    Abuhalimeh, Batool
    Khirfan, Ghaleb
    Dweik, Raed A.
    Tang, W. H. Wilson
    Tonelli, Adriano R.
    CHEST, 2018, 154 (03) : 541 - 549
  • [23] Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension
    Morrisroe, Kathleen
    Stevens, Wendy
    Huq, Molla
    Prior, David
    Sahhar, Jo
    Ngian, Gene-Siew
    Celermajer, David
    Zochling, Jane
    Proudman, Susanna
    Nikpour, Mandana
    ARTHRITIS RESEARCH & THERAPY, 2017, 19
  • [24] Pulmonary arterial hypertension in adult congenital heart disease
    Brida, Margarita
    Gatzoulis, Michael A.
    HEART, 2018, 104 (19) : 1568 - 1574
  • [25] The Challenges in Managing Pulmonary Arterial Hypertension Associated with Congenital Heart Disease
    Lu, Chun-Wei
    ACTA CARDIOLOGICA SINICA, 2015, 31 (06) : 516 - 517
  • [26] Nailfold capillaroscopic changes in patients with idiopathic pulmonary arterial hypertension and systemic sclerosis-related pulmonary arterial hypertension
    Corrado, A.
    Correale, M.
    Mansueto, N.
    Monaco, I.
    Carriero, A.
    Mele, A.
    Colia, R.
    Di Biase, M.
    Cantatore, F. P.
    MICROVASCULAR RESEARCH, 2017, 114 : 46 - 51
  • [27] Postoperative pulmonary complications in contemporary cohort of patients with pulmonary hypertension
    Kruthiventi, S. Chandralekha
    Kane, Garvan C.
    Sprung, Juraj
    Weingarten, Toby N.
    Warner, Mary Ellen
    BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2019, 19 (04) : 392 - 399
  • [28] Screening for pulmonary arterial hypertension in systemic sclerosis: A systematic literature review
    Bruni, Cosimo
    De Luca, Giacomo
    Lazzaroni, Maria Grazia
    Zanatta, Elisabetta
    Lepri, Gemma
    Airo, Paolo
    Dagna, Lorenzo
    Doria, Andrea
    Matucci-Cerinic, Marco
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2020, 78 : 17 - 25
  • [29] The economic burden of systemic sclerosis related pulmonary arterial hypertension in Australia
    Morrisroe, Kathleen
    Stevens, Wendy
    Sahhar, Joanne
    Ngian, Gene-Slew
    Ferdowsi, Nava
    Hansen, Dylan
    Patel, Shreeya
    Hill, Catherine L.
    Roddy, Janet
    Walker, Jennifer
    Proudman, Susanna
    Nikpour, Mandana
    BMC PULMONARY MEDICINE, 2019, 19 (01)
  • [30] Pulmonary Involvement in Systemic Sclerosis and Pulmonary Arterial Hypertension (PAH)
    Graefenstein, K.
    AKTUELLE RHEUMATOLOGIE, 2011, 36 (01) : 47 - 53